Stock CYTO ALTAMIRA THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Altamira Therapeutics Nasdaq

Equities

CYTO

BMG0360L2099

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-24 EDT 		5-day change 1st Jan Change
1.78 USD +4.09% Intraday chart for Altamira Therapeutics +14.10% -48.85%
05-01 Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation CI
04-24 Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal CI

Valuation

Fiscal Period: December 2019 2023 2024 2025 2026
Capitalization 1 5.174 1.164 3.645 - -
Enterprise Value (EV) 1 3.789 1.164 3.645 3.645 3.645
P/E ratio -0.69 x -0.37 x -0.42 x -0.56 x -1.01 x
Yield - - - - -
Capitalization / Revenue - - - - 0.81 x
EV / Revenue - - - - 0.81 x
EV / EBITDA -715,778 x - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 8.26 398 2,240 - -
Reference price 2 626.7 2.927 1.627 1.627 1.627
Announcement Date 4/16/20 4/10/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2023 2024 2025 2026
Net sales 1 - - - - 4.476
EBITDA -7.228 - - - -
EBIT 1 -7.259 - -7.846 -10.29 -8.683
Operating Margin - - - - -194%
Earnings before Tax (EBT) 1 -6.826 - -7.84 -10.17 -8.531
Net income 1 -6.632 -3.869 -7.84 -10.17 -8.531
Net margin - - - - -190.61%
EPS 2 -912.0 -7.880 -3.890 -2.890 -1.610
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 4/16/20 4/10/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 - - - - -
EBITDA - - - - -
EBIT -3.152 - - - -
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income -3.028 - - - -
Net margin - - - - -
EPS 2 -248.0 -2.140 -1.750 - -
Dividend per Share - - - - -
Announcement Date 4/16/20 - - - -
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position 1.38 - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 3.02 - - - -
Capex / Sales - - - - -
Announcement Date 4/16/20 4/10/24 - - -
1CHF in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
ARGENX SE Stock argenx SE
-1.54% 22.1B
GENMAB A/S Stock Genmab A/S
-8.28% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.70% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CYTO Stock
  4. CYTO Stock
  5. Financials Altamira Therapeutics